BRIACELL THERAPEUTICS CORP. Adjustments For Unrealised Foreign Exchange Losses Gains
BRIACELL THERAPEUTICS CORP. (BCTX) reported Adjustments For Unrealised Foreign Exchange Losses Gains of $884.54 thousand for the 9-month period ending 2021-04-30, per its 6-K filed 2022-06-13.
Discontinued › Income Statement › Other Income
ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains · last filed 2022-06-13
- 2021-04-30: Adjustments For Unrealised Foreign Exchange Losses Gains 9 month $884.54K.
| Period end | Adjustments For Unrealised Foreign Exchange Losses Gains 9 month |
|---|---|
| 2021-04-30 | $884.54K 6-K · filed 2022-06-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |